Home › Breast Cancer › NCT05496829
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * Women or men age \>18 years * Diagnosed with stage I-III breast cancer prescribed endocrine therapy * Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation) * Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention * Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire Exclusion Criteria: * Evidence of breast cancer recurrence * Non-English or Non-Spanish speaking * Not cognitively able to complete study requirements * Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR * Inability to provide informed consent
About the study
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
What is being tested
- Multicomponent Adherence Intervention (behavioral)
- Usual Care (other)
Sponsor: Columbia University · Participants: 350 · Started: Mar 2, 2023
Contact the study team
- Research Nurse Navigator · Phone: 212-342-5162
Official record on ClinicalTrials.gov — NCT05496829
Locations in the U.S.
| New York | Columbia University Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.